Antibody-Drug Conjugates Stocks
Biotechnology firms in this vertical specialize in engineered therapeutic modalities that combine the targeting precision of monoclonal antibodies with the high potency of cytotoxic payloads via chemical linkers.
As of Oct 23, 2026, Antibody-Drug Conjugates has 30 US-listed companies worth $287B combined. The median member moved +3.7% over the past week; ATNM led among the 25 largest at +34.5% and MGNX trailed at -30.8%.
Companies in Antibody-Drug Conjugates
- AZN – AstraZeneca PLC, $266B
- KOD – Kodiak Sciences Inc, $5.4B
- IDYA – Ideaya Biosciences Inc, $3.5B
- PBLS – Parabilis Medicines, Inc. Common Stock, $3.1B
- IMNM – Immunome Inc, $2.1B
- ZYME – Zymeworks Inc. Common Stock, $1.9B
- ANL – Adlai Nortye Ltd. American Depositary Shares, $999M
- AVBP – ArriVent BioPharma, Inc. Common Stock, $821M
- CTMX – CytomX Therapeutics Inc, $556M
- CBIO – Crescent Biopharma, Inc., $532M
- BCYC – Bicycle Therapeutics Ltd, $245M
- PYXS – Pyxis Oncology Inc, $220M
- MGNX – MacroGenics Inc, $218M
- ADCT – ADC Therapeutics SA, $217M
- WHWK – Whitehawk Therapeutics, Inc., $194M
- STRO – Sutro Biopharma, $181M
- ALXO – Alx Oncology Holdings , $173M
- ADAG – Adagene Inc, $165M
- IPHA – Innate Pharma, $160M
- VRXA – Veraxa Biotech AG Ordinary Shares, $156M
- CRBP – Corbus Pharmaceuticals Holding, $85.5M
- OSTX – OS Therapies Incorporated, $75.8M
- PDSB – PDS Biotechnology Corp, $66.4M
- ATNM – Actinium Pharmaceuticals Inc, $30.6M
- AKTX – Akari Therapeutics PLC, $21.2M
- CLRB – Cellectar Biosciences Inc, $13.1M
- CUBT – Curative Biotechnology Inc, $8.4M
- BOLT – Bolt Biotherapeutics, $7.7M
- BCAB – Bioatla Inc, $2.5M
- VINC – Vincerx Pharma, Inc. Common Stock, $68,045